The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Bibliography

• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369(9563):767-78
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Gallo L, Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008;35(2):343-8
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201(9):1479-86
   PubMed Web of Science ®Google Scholar
• Ravelli A, Magni-Manzoni S, Pistorio A, Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146(5):598-604
   PubMed Web of Science ®Google Scholar
• Prieur AM, Stephan JL. Macrophage activation syndrome in rheumatic diseases in children. Rev Rhum Ed Fr 1994;61(6):447-51
   PubMedGoogle Scholar
• Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004;50(3):689-98
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34(5):1133-8
   PubMed Web of Science ®Google Scholar
• Gattorno M, Piccini A, Lasiglie D, The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58(5):1505-15
   PubMed Web of Science ®Google Scholar
• Oen K, Malleson PN, Cabral DA, Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29(9):1989-99
   PubMed Web of Science ®Google Scholar
• Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009;72(Suppl 1):20-5
   PubMed Web of Science ®Google Scholar
• Russo RA, Katsicas MM. Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. J Rheumatol 2008;35(6):1151-6
   PubMed Web of Science ®Google Scholar
• MMWR Data Source. 2003 Medical expenditure panel survey. MMWR 2007;56(01):4-7
   PubMedGoogle Scholar
• Minden K, Niewerth M, Listing J, The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol 2009;27(5):863-9
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63(7):836-42
   PubMed Web of Science ®Google Scholar
• Spiegel LR, Schneider R, Lang BA, Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43(11):2402-9
   PubMed Web of Science ®Google Scholar
• Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005;17(5):612-16
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63(12):1638-44
   PubMed Web of Science ®Google Scholar
• Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36(5):1078-82
   PubMed Web of Science ®Google Scholar
• Ilowite N, Porras O, Reiff A, Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28(2):129-37
   PubMed Web of Science ®Google Scholar
• Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005;5(5):683-90
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998-1006
   PubMed Web of Science ®Google Scholar
• Eisenberg SP, Evans RJ, Arend WP, Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343(6256):341-6
   PubMed Web of Science ®Google Scholar
• Granowitz EV, Porat R, Mier JW, Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992;4(5):353-60
   PubMed Web of Science ®Google Scholar
• Nielsen JT. Handling of proteins in isolated and in vitro perfused proximal tubules from rabbit kidney. Dan Med Bull 1990;37(3):197-210
   PubMed Web of Science ®Google Scholar
• Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74(1):85-94
   PubMed Web of Science ®Google Scholar
• Bendele A, McAbee T, Sennello G, Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42(3):498-506
   PubMed Web of Science ®Google Scholar
• Lequerre T, Quartier P, Rosellini D, Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67(3):302-8
   PubMed Web of Science ®Google Scholar
• Irigoyen P, Olson J, Hom C, Ilowite N. Treatment of systemic onset juvenile idiopathic arthritis with anakinra. Case series. Pediatr Rheumatol Online J 2006;4(2):123-34
   Google Scholar
• Livermore P, Woo P. Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis. Poster Abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):32
   Google Scholar
• Ohlsson V, Baildam E, Foster H, Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008;47(4):555-6
   PubMed Web of Science ®Google Scholar
• Pontikaki I, Gerloni V, Gattinara M, Fantini F. Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF. Poster Abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):30
   Google Scholar
• Wulffraat NM, De Jager W, Prakken B, Kuis W. Early effects of Anakinra in in corticosteroid naive SOJIA patients. Poster Abstract at PReS Congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):29
   Google Scholar
• Zeft A, Hollister R, LaFleur B, Anakinra for systemic juvenile arthritis: the Rocky mountain experience. J Clin Rheumatol 2009;15(4):161-4
   PubMed Web of Science ®Google Scholar
• Sandborg C, Holmes TH, Lee T, Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol 2006;33(11):2322-9
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS). Poster abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):27
   Google Scholar
• Canna S, Frankovich J, Higgins G, Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J 2009;7:21
   PubMed Web of Science ®Google Scholar
• Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006;33(10):2081-4
   PubMed Web of Science ®Google Scholar
• Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4(11):615-20
   PubMedGoogle Scholar
• Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31(10):2071-5
   PubMed Web of Science ®Google Scholar
• Miettunen PM, Narendran A, Jayanthan A, Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2010 [Epub ahead of print]
   Google Scholar
• Cron RQ, Beukelman T. Guilt by association – what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
   PubMed Web of Science ®Google Scholar
• Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) 2010;62(6):800-4
   PubMed Web of Science ®Google Scholar
• Neubert A, Wong IC, Bonifazi A, Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 2008;58(5-6):316-22
   PubMed Web of Science ®Google Scholar
• Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999;48(1):15-18
   PubMed Web of Science ®Google Scholar
• Conroy S, Choonara I, Impicciatore P, Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320(7227):79-82
   PubMed Web of Science ®Google Scholar
• Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002;324(7349):1312-13
   PubMed Web of Science ®Google Scholar
• Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr Drugs 2009;11(1):45-7
   PubMedGoogle Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48(10):2750-62
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42):1-229
   Web of Science ®Google Scholar
• Finckh A, Bansback N, Marra CA, Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009;151(9):612-21
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40(7):1202-9
   PubMed Web of Science ®Google Scholar